Cycurion (NASDAQ:CYCU) shares rally further on $54.6 million contract as investors watch cash flow schedule

CYCU finished regular trading on July 30 at $1.61, up 495.85%. In early premarket action on July 31, the price was around $2.23, representing a further 38% rise. marketscreener.com The primary driver was a $54.6 million state contract to modernize a health system, spanning ten years. GlobeNewswire Volume on July 30 reached 617.5 million shares, an unusually high churn for the stock. This figure is about 54 times the share count reported as of July 2. Yahoo Finance The jump in trading volume points to heightened speculative activity tied to the contract announcement.

The contract has a total value of about $54.6 million over a ten-year period. Management anticipates yearly revenue above $5 million, with work scheduled to begin in November 2026. GlobeNewswire Cycurion reported revenue of $15.1 million for fiscal 2025. SEC Revenue for the first quarter of 2026 reached $3.27 million, reflecting a decrease of 15.5% from a year earlier. SEC Trailing twelve-month revenue totals close to $14.5 million. Annual contract revenue would represent over 34% of that figure. No details on contract margins or itemized billing schedules were included in the announcement.

Revenue for the first quarter declined 15.5% to $3.27 million, compared with $3.87 million previously. Gross profit rose to $688,358, lifting gross margin to 21.1%. One year earlier, margin was 17.5%, and sequentially, it stood at 12.1%. SEC Net loss attributable to Cycurion decreased to $2.13 million versus a sequential loss of $5.11 million. Selling, general and administrative expense came to $2.74 million. SEC That figure was nearly quadruple the quarterly gross profit. Progress is evident, but not yet complete.

As of March 31, Cycurion reported cash of $2.03 million, compared with a quarterly operating cash burn of $2.89 million. Working-capital deficit stood near $12.0 million. SEC Cycurion said there is substantial doubt about its ability to remain a going concern and anticipates substantial operating losses in the coming years. SEC Following quarter close, the company raised $3.3 million by selling 4.63 million shares through July 2. Kscope This issuance increased cash reserves but heightened reliance on equity financing. The financial position remains precarious.

The number of common shares increased from 5.51 million on March 31 to 11.47 million by July 2, a rise of 108% in just under three months. SEC The 4.63 million post-quarter shares brought in $3.3 million, equating to an average price of $0.71 per share. Kscope The S-1 filed in July registered 25 million shares for resale through the Yield Point equity line, along with 888,888 shares tied to the Secuvant deal. Kscope In total, registered shares were more than 225% of the outstanding common shares as of July 2. Registration does not require immediate issuance, and the current share count could be higher.

Yes. Nasdaq issued a delisting notice on July 10 after the share price remained under $1 for 31 business days. The company did not qualify for the usual 180-day grace period due to its reverse split scheduled for October 2025. SEC A prompt appeal from the company allows shares to continue trading while Nasdaq evaluates the matter. Cycurion anticipates its case will be heard in August 2026, but ongoing listing cannot be guaranteed. SEC The close above $1 on July 30 is a positive step, yet a single session is not enough to conclude the appeal process. Shareholders gave approval for reverse-split ratios ranging from 3-for-1 to 75-for-1, with a 250-for-1 total limit. SEC

A July 29 filing indicated the transaction was still pending ahead of the July 31 outside date. One crucial employee had declined to join Cycurion following completion. Additionally, Halo and havenX had yet to submit the necessary audited financial statements or cash calculations. SEC According to the filing, there appeared little chance of fulfilling a material closing condition. The deal was not officially terminated at that point, leaving room for renegotiation. Management previously projected annualized revenue of $7 million, with an estimated 55% gross margin. SEC If the deal does not complete, the $21 million-to-$22 million one-year revenue projection should not be included.

Based on July 2’s figure of 11.47 million shares, the closing price of $1.61 resulted in a market capitalization of $18.5 million. marketscreener.com Trailing revenue stood at an estimated $14.5 million, putting the valuation at about 1.27 times sales. SEC Assuming the contract is fully incremental, annual revenue would top $19.5 million. Keeping the same sales multiple, this would translate to roughly $2.15 per share. At a two-times-sales multiple and no dilution, the figure rises to $3.40; both calculations are illustrative only. The single analyst target remains $7, set ahead of recent dilution and the delisting notice. Investing.com Using the July 2 share amount, a $7 share price would value equity at about $80.3 million.